Aurobindo Pharma announced its subsidiary Eugia Pharma received a USFDA warning letter. This follows an inspection of their Telangana formulation manufacturing facility. The inspection concluded with four observations and an official action indicated status. The company stated existing US market supplies remain unaffected by this development. Aurobindo Pharma continues its commitment to ongoing compliance with the US FDA.